Compare OGE & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGE | QGEN |
|---|---|---|
| Founded | 1902 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 10.2B |
| IPO Year | N/A | 1996 |
| Metric | OGE | QGEN |
|---|---|---|
| Price | $43.35 | $46.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $47.90 | $47.81 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 02-18-2026 | 02-04-2026 |
| Dividend Yield | 3.90% | ★ 5.07% |
| EPS Growth | 29.01 | ★ 331.25 |
| EPS | ★ 2.49 | 1.94 |
| Revenue | ★ $3,294,800,000.00 | $2,070,781,000.00 |
| Revenue This Year | $7.16 | $7.12 |
| Revenue Next Year | $4.28 | $5.95 |
| P/E Ratio | ★ $17.52 | $24.58 |
| Revenue Growth | ★ 18.03 | 5.32 |
| 52 Week Low | $40.80 | $39.61 |
| 52 Week High | $47.33 | $54.61 |
| Indicator | OGE | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 48.15 |
| Support Level | $42.40 | $46.75 |
| Resistance Level | $44.00 | $49.01 |
| Average True Range (ATR) | 0.64 | 1.03 |
| MACD | 0.16 | 0.06 |
| Stochastic Oscillator | 64.43 | 38.84 |
OGE Energy is a holding company for Oklahoma Gas & Electric, a regulated utility with electricity generation, transmission, and distribution service for 900,000 customers in Oklahoma and western Arkansas. In December 2021, OGE divested its 25.5% stake in Enable Midstream Partners, an oil and gas services company it created in 2013 through a unit exchange merger with Energy Transfer. OGE sold its 95.4 million limited partner units of Energy Transfer throughout 2022. OGE sold its retail gas business in 1928 and no longer has any gas operations.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).